Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Amlexanox and Meldonium — mechanism, dosing, side effects, legal status, and pricing.
Amlexanox is a non-peptide small-molecule 2-amino-chromeno[2,3-b]pyridine-3-carboxylic acid derivative (CAS 68302-57-8, MW 298.29 g/mol). Originally approved in 1996 as a topical oral paste for aphthous ulcers (FDA, now discontinued) and in Japan for allergic conditions, it was later characterized as a selective ATP-competitive inhibitor of the non-canonical IκB kinases TBK1 and IKKε. It is NOT approved for any metabolic, obesity, or performance indication; it is sold by research-chemical vendors labeled research-use-only and promoted off-label by biohacking outlets for fat loss. No validated human dose exists for metabolic applications.
Meldonium (Mildronate) is a small-molecule carnitine-biosynthesis inhibitor and anti-ischemic metabolic modulator — not a peptide. It is an approved prescription drug for cardiovascular indications in several ex-Soviet states but is not FDA- or EMA-approved, and it is WADA-prohibited (added January 2016, of Sharapova notoriety). It is also sold as a gray-market research chemical.
Amlexanox
Meldonium
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Amlexanox
Meldonium
No pricing data yet.
Check Meldonium prices →COA corpus from Disclosed Labs — independently tested batches only.
Amlexanox
1
COAs
99.6%
Avg purity
1
Labs
Meldonium
2
COAs
99.9%
Avg purity
2
Labs
In diet-induced obese and ob/ob mice, amlexanox treatment increased energy expenditure via thermogenesis, produced weight loss, improved insulin sensitivity, and decreased hepatic steatosis; these metabolic benefits require intact FGF21 signaling. In LDL-receptor-knockout mice on Western diet, amlexanox reduced triglycerides, cholesterol, circulating monocytes/eosinophils, macrophage plaque accumulation, and atherosclerotic lesion size. One randomized, double-blind, placebo-controlled proof-of-concept trial in 42 obese patients with type 2 diabetes and NAFLD showed statistically significant HbA1c and fructosamine reductions versus placebo, with a responder subgroup showing improved insulin sensitivity and reduced hepatic fat; rash occurred in several participants (two required biopsy). No obesity or diabetes indication has been approved by any regulator.
In rat ischemia-reperfusion models, meldonium (100–200 mg/kg) reduced myocardial infarct size ~30% and protected liver, brain, and endothelial function. In humans it is used clinically (in approving markets) for chronic heart failure and angina at 500 mg twice daily, but there is no FDA/EMA-registered pivotal efficacy trial. Urinary detection persists for weeks-to-months, central to doping cases. Not FDA/EMA-approved; not a peptide.
Amlexanox and Meldonium are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs